Byam Rebecca 4
4 · HCW Biologics Inc. · Filed May 9, 2025
Insider Transaction Report
Form 4
Byam Rebecca
Chief Financial Officer
Transactions
- Purchase
Common Stock
2025-05-08$26.00/sh+8,462$220,012→ 43,010 total - Purchase
Common Stock Purchase Warrant
2025-05-07+4,231→ 4,231 totalExercise: $26.00From: 2025-05-07Exp: 2030-05-07→ Common Stock (4,231 underlying)
Footnotes (1)
- [F1]These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company.